<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04586023</url>
  </required_header>
  <id_info>
    <org_study_id>GN42272</org_study_id>
    <secondary_id>2020-001168-28</secondary_id>
    <nct_id>NCT04586023</nct_id>
  </id_info>
  <brief_title>Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS)</brief_title>
  <acronym>FENhance</acronym>
  <official_title>A Phase III Multicenter Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Adult Patients With Relapsing Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the efficacy and safety of fenebrutinib on disability progression and&#xD;
      relapse rate in adult participants with RMS. Eligible participants will be randomized 1:1 to&#xD;
      either fenebrutinib or teriflunomide. Open-Label Extension (OLE) phase is contingent on a&#xD;
      positive benefit-risk result in the Primary Analysis of the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2021</start_date>
  <completion_date type="Anticipated">November 27, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Sponsor will also be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized Relapse Rate (ARR)</measure>
    <time_frame>Minimum of 96 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to onset of composite 12-week confirmed disability progression (cCDP12)</measure>
    <time_frame>Minimum of 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of composite 24-week confirmed disability progression (cCDP24)</measure>
    <time_frame>Minimum of 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of 12-week confirmed disability progression (CDP12)</measure>
    <time_frame>Minimum of 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of 24-week confirmed disability progression (CDP24)</measure>
    <time_frame>Minimum of 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of T1Gd+ lesions, new and/or enlarging T2-weighted lesions as detected by MRI</measure>
    <time_frame>Baseline, Weeks 12, 24, 48 and 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Total Brain Volume from Week 24 as assessed by MRI</measure>
    <time_frame>From Week 24 to Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Participant-Reported Physical Impacts of Multiple Sclerosis (MS)</measure>
    <time_frame>Baseline, Weeks 12, 24, 36, 48, 60, 72, 84 and 96</time_frame>
    <description>Measured by the Multiple Sclerosis, 29-Item [MSIS-29] physical scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of 12-week confirmed 4-point worsening in Symbol Digit Modality Test (SDMT) score</measure>
    <time_frame>Minimum of 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 48 in the Concentration of Serum Neurofilament Light chain (NfL)</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to 3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of fenebrutinib at specified timepoints</measure>
    <time_frame>Up to 3.5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">736</enrollment>
  <condition>Relapsing Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>fenebrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive oral fenebrutinib with teriflunomide-matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>teriflunomide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive oral teriflunomide with fenebrutinib-matching placebo in a blinded fashion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fenebrutinib</intervention_name>
    <description>Participants will receive fenebrutinib.</description>
    <arm_group_label>fenebrutinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>teriflunomide</intervention_name>
    <description>Participants will receive teriflunomide.</description>
    <arm_group_label>teriflunomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo.</description>
    <arm_group_label>fenebrutinib</arm_group_label>
    <arm_group_label>teriflunomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Expanded Disability Status Scale (EDSS) score of 0 - 5.5 at screening.&#xD;
&#xD;
          -  A diagnosis of RMS in accordance with the revised 2017 McDonald Criteria.&#xD;
&#xD;
          -  Ability to complete the 9-Hole Peg Test (9-HPT) for each hand in &lt; 240 seconds.&#xD;
&#xD;
          -  Ability to perform the Timed 25-Foot Walk Test (T25FWT) in &lt;150 seconds.&#xD;
&#xD;
          -  For female participants of childbearing potential: agreement to remain abstinent&#xD;
             (refrain from heterosexual intercourse) or use contraceptive measures, and refrain&#xD;
             from donating eggs.&#xD;
&#xD;
          -  For male participants: agreement to remain abstinent (refrain from heterosexual&#xD;
             intercourse) or use contraceptive measures, and refrain from donating sperm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Disease duration of &gt; 10 years from the onset of symptoms and an EDSS score at&#xD;
             screening &lt; 2.0.&#xD;
&#xD;
          -  Female participants who are pregnant or breastfeeding, or intending to become&#xD;
             pregnant.&#xD;
&#xD;
          -  Male participants who intend to father a child during the study.&#xD;
&#xD;
          -  A diagnosis of PPMS or non-active SPMS.&#xD;
&#xD;
          -  Any known or suspected active infection at screening, including but not limited to a&#xD;
             positive screening tests for Hepatitis B and C, an active or latent or inadequately&#xD;
             treated infection with tuberculosis (TB), a confirmed or suspected progressive&#xD;
             multifocal leukoencephalopathy (PML).&#xD;
&#xD;
          -  History of cancer including hematologic malignancy and solid tumors within 10 years of&#xD;
             screening.&#xD;
&#xD;
          -  Known presence of other neurological disorders, clinically significant cardiovascular,&#xD;
             psychiatric, pulmonary, renal, hepatic, endocrine, metabolic or gastrointestinal&#xD;
             disease.&#xD;
&#xD;
          -  Rare hereditary problems of galactose intolerance, total lactase deficiency, or&#xD;
             glucose-galactose malabsorption.&#xD;
&#xD;
          -  Hypoproteinemia.&#xD;
&#xD;
          -  Participants with severe renal or hepatic disease impairment or Gilbert's Syndrome.&#xD;
&#xD;
          -  Participants with significantly impaired bone marrow function or significant anemia,&#xD;
             leukopenia, neutropenia or thrombocytopenia.&#xD;
&#xD;
          -  Any concomitant disease that may require chronic treatment with systemic&#xD;
             corticosteroids or immunosuppressants during the course of the study.&#xD;
&#xD;
          -  History of alcohol or other drug abuse within 12 months prior to screening.&#xD;
&#xD;
          -  History of or currently active primary or secondary (non-drug-related)&#xD;
             immunodeficiency, including known history of HIV infection.&#xD;
&#xD;
          -  Inability to complete an MRI scan.&#xD;
&#xD;
          -  Adrenocorticotropic hormone or systemic corticosteroid therapy within 4 weeks prior to&#xD;
             screening (inhaled and topical corticosteroids are allowed).&#xD;
&#xD;
          -  Receipt of a live-attenuated vaccine within 6 weeks prior to randomization.&#xD;
&#xD;
          -  Any previous treatment with immunomodulatory or immunosuppressive medication without&#xD;
             an appropriate washout period.&#xD;
&#xD;
        OLE Inclusion Criteria:&#xD;
&#xD;
          -  Completed the Double-Blind Treatment (DBT) phase of the study (remaining on study&#xD;
             treatment; no other Disease-Modifying Therapy (DMT) administered) and who, in the&#xD;
             opinion of the investigator, may benefit from treatment with fenebrutinib.&#xD;
&#xD;
          -  Participants randomized to the teriflunomide treatment arm during the DBT phase must&#xD;
             undergo the ATEP prior to the first administration of open-label fenebrutinib.&#xD;
&#xD;
          -  For female participants of childbearing potential: agreement to remain abstinent&#xD;
             (refrain from heterosexual intercourse) or use contraceptive measures, and refrain&#xD;
             from donating eggs.&#xD;
&#xD;
          -  For male participants: agreement to remain abstinent (refrain from heterosexual&#xD;
             intercourse) or use contraceptive measures, and refrain from donating sperm.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GN42272 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>North Central Neurology Associates</name>
      <address>
        <city>Cullman</city>
        <state>Alabama</state>
        <zip>35058</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Xenoscience</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center; Stanford Neuroscience Health Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute at Harbor-UCLA</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>KI Health Partners, LLC; New England Institute for Clinical Research</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SFM Clinical Research, LLC</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33487</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>American Health Network Institute, LLC</name>
      <address>
        <city>Avon</city>
        <state>Indiana</state>
        <zip>46123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neuro Institute of New England P.C.; Research</name>
      <address>
        <city>Foxboro</city>
        <state>Massachusetts</state>
        <zip>02035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis</name>
      <address>
        <city>Owosso</city>
        <state>Michigan</state>
        <zip>48867</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati; Department of Neurology</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providence Neurological Specialties</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hope Neurology</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Central Texas Neurology Consultants</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Integrated Neurology Services PLLC</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin, Inc.</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-3596</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien; Univ.Klinik fuer Neurologie</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Misericordia; de Belo Horizonte</name>
      <address>
        <city>Belo Horizonte</city>
        <state>MG</state>
        <zip>30150-221</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Núcleo de Pesquisa do Rio Grande do Sul</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90430-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Lucas - PUCRS</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Neurologica; Neurocirurgica de Joinville</name>
      <address>
        <city>Joinville</city>
        <state>SC</state>
        <zip>89202-190</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisas Clinicas; CPCLIN</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01228-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Marcelina; AME - Ambulatório de Especialidades Médicas</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>08270-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMHAT Dr. Georgi Stranski; 2nd Neurology Clinic, Occupational Diseases</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital - General Campus; Department of Neurology - Multiple Sclerosis</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Recherche Sepmus, Inc.</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2J2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MUCH - Montreal Neurological Institute &amp; Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aalborg Universitetshospital; Neurologisk Afdeling og Neurofysiologisk Afdeling; Skleroseamb.</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sydvestjysk Sygehus Esbjerg; Neurologisk Afd., Skleroseklinikken</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sydjysk Skleroseklinik - Sønderborg</name>
      <address>
        <city>Sønderborg</city>
        <zip>6400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Pellegrin-CHU de Bordeaux; Service de Neurologie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Gabriel Montpied CHU de Clermont-Ferrand; Service de Neurologie B</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Gui de Chauliac; Neurologie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Pasteur; Service de Neurologie</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles Nicolle; Service de Neurologie</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU toulouse - Hôpital Purpan; Departement de Neurologie</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Larisa; Neurology Clinic</name>
      <address>
        <city>Larisa</city>
        <zip>411 10</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AHEPA Univ. General Hospital of Thessaloniki; B' Neurology Dept.</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 36</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Ioannina; Neurology Clinic</name>
      <address>
        <city>Ιωαννινα</city>
        <zip>455 00</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>A. O. U. Federico II; Dip Neuroscienze, Scienze Riproduttive ed Odontostomatologiche</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale S.Camillo Forlanini; UOSD Day Hospital Neurologico e Neurochirurgico</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NCL Institute Neuroscience</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00178</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fond. Istituto Neurologico C.Besta; UO Neurologia IV - Neuroimmunologia Malattie Neuromuscolari</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Neurologico C. Mondino-Dip. Neurologia Neuroriabilitazione S.S. Sclerosi Multipla</name>
      <address>
        <city>Pavia</city>
        <state>Lombardia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Neurologico Neuromed; Centro per lo Studio e la Cura della Sclerosi Multipla</name>
      <address>
        <city>Pozzilli</city>
        <state>Molise</state>
        <zip>86077</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Binaghi; Centro Sclerosi Multipla</name>
      <address>
        <city>Cagliari</city>
        <state>Sardegna</state>
        <zip>09126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Giaccone; UOC Neurologia e Neurofisiopatologia-Amb Sclerosi Multipla</name>
      <address>
        <city>Palermo</city>
        <state>Sicilia</state>
        <zip>90129</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>41931</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Grupo Médico Camino S.C.</name>
      <address>
        <city>Ciudad de México</city>
        <state>Mexico CITY (federal District)</state>
        <zip>03600</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinstile S.A de C.V.</name>
      <address>
        <city>Mexico City</city>
        <state>Mexico CITY (federal District)</state>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Unidad de Investigación en Salud; Psiquiatria</name>
      <address>
        <city>Chihuahua</city>
        <zip>31203</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Unidad de investigacion en salud (UIS); Neurociencias</name>
      <address>
        <city>Ciudad de México</city>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>COPERNICUS Podmiot Leczniczy Sp. z o. o. Szpital im. M. Kopernika; Oddział Neurologiczny</name>
      <address>
        <city>Gdansk</city>
        <zip>80-803</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>RESMEDICA Spolka z o.o.</name>
      <address>
        <city>Kielce</city>
        <zip>25-726</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Neurologii Klinicznej</name>
      <address>
        <city>Krakow</city>
        <zip>31-505</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Malopolskie Centrum Diagnostyczne MEDICAL Sp. z o. o.</name>
      <address>
        <city>Krakow</city>
        <zip>31-637</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MT Medic Krosno</name>
      <address>
        <city>Krosno</city>
        <zip>38-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Neurologii Krzysztof Selmaj</name>
      <address>
        <city>Lodz</city>
        <zip>90-324</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-561</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instytut Zdrowia Dr Boczarska-Jedynak Sp. z o.o. Sp. k.</name>
      <address>
        <city>Oswiecim</city>
        <zip>32-600</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NZOZ NEURO-KARD Ilkowski i Partnerzy Sp. Partn. Lek</name>
      <address>
        <city>Poznań</city>
        <zip>61-853</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wro Medica</name>
      <address>
        <city>Wrocław</city>
        <zip>51-685</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IBISMED Wielospecjalistyczne Centrum Medyczne</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Center of Social Significant Disease</name>
      <address>
        <city>Sankt-peterburg</city>
        <state>Leningrad</state>
        <zip>197110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>FGBU Federal Center of cerebrovascular pathology and stroke</name>
      <address>
        <city>Moskva</city>
        <state>Moskovskaja Oblast</state>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional clinical hospital named after prof. S.V. Ochapovsky</name>
      <address>
        <city>Krasnodar</city>
        <zip>350086</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital N.A. Semashko; Neurology</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hacettepe University Medical Faculty; Neurology</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gazi University Medical Faculty; Departmant of Neurology.</name>
      <address>
        <city>Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi - Cerrahpasa Cerrahpasa Tip Fakultesi; Noroloji Anabilim Dali</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sancaktepe Training and Research Hospital; Neurology</name>
      <address>
        <city>Istanbul</city>
        <zip>34785</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kocaeli University Hospital; Department of Neurology</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Selcuk University Medical Faculty; Norology department</name>
      <address>
        <city>Konya</city>
        <zip>42131</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ege Üniversitesi Tip Fakültesi</name>
      <address>
        <city>Lzmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mersin University Medical Faculty; Neurology</name>
      <address>
        <city>Mersin</city>
        <zip>33079</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ondokuz Mayis University School of Medicine; Neurology</name>
      <address>
        <city>Samsun</city>
        <zip>55239</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karadeniz Tecnical Uni. Med. Fac.; Neurology</name>
      <address>
        <city>Trabzon</city>
        <zip>61080</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 8, 2020</study_first_submitted>
  <study_first_submitted_qc>October 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriflunomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

